`
`For over 30 years, our mission has been to use the power of science to bring new medicinesto patients... over
`and overagain.
`
`Regeneron (NASDAQ: REGN) is a leading biotechnology companythatinvents life-trans forming
`medicines for people with serious diseases. Founded and led for over 30 years by physician-
`scientists, our unique ability to repeatedly and consistently translate science into medicine hasled
`to nine FDA-approved treatments and numerous product candidates in development, nearly all of
`which were homegrown in our laboratories. Our medicines and pipeline are designed to help
`patients with eye diseases,allergic and inflammatory diseases, cancer, cardiovascular and
`metabolic diseases, pain, hematologic diseases, infectious diseases and rare diseases.
`
`Regeneronis accelerating and improving the traditional drug development process through our
`proprietary VelociSuite® technologies, such as Velocimmune®, which uses unique genetically
`humanized mice to produceoptimized fully human antibodies and bispecific antibodies, and
`through ambitious research initiatives such as the Regeneron Genetics Center®, whichis
`conducting one of the largest genetics sequencing efforts in the world.
`
`Mylan v. Regeneron
`IPR2021-00881
`U.S. Pat. 9,254,338
`Exhibit 2246
`
`Every day, we apply¢
`technologiesandrele:
`people with serious diseaSt
`Th
`
`
`Followus: W in fFL> 1/4
`
`2020 wasa challenging butinspiring RegeneronNews:Oct22nd
`
`
`
`year: from creating a new medicine in Dupixent® (dupilumab)isthe
`record time while advancing a diverse
`First Biologic to Significantly
`pipeline to delivering needed medicines
`ReduceItch and Skin Lesionsin
`despite pandemic conditions.
`Phase 3 Trial for Prurigo
`
`m=
`Bes
`CaF
`
`Nodularis, Demonstrating the Role
`
`Exhibit 2246
`
`Page 01 of 04
`
`Exhibit 2246
`Page 01 of 04
`
`
`
`Regeneron by the numbers
`
`30+
`years of scientific leadership
`
`OK+
`employees worldwide
`
`employees with an MD, PhD
`or PharmD degree
`
`consecutive year as one of
`Fast Company Best
`Workplaces for Innovators
`
`ranking in Science
`magazine's global Top
`Employer surveyfor six of the
`past nine years
`
`volunteers for virtual Day for
`Doing Good 2020
`
`9
`
`FDA-approved medicines
`
`98%
`
`of our waste diverted from
`
`landfill, surpassing our 2025
`global responsibility goal
`
`~100%
`of drug candidates invented
`and developed in-house
`
`30+
`
`exomes sequenced to date
`
`peer-reviewed publications in
`2020
`
`product candidatesin clinical
`development across multiple
`therapeutic areas
`
`Honors and awards
`
`Fast Company:Best Workplacesfor Innovators, 2021
`
`Great Place To Work: Fortune 100 Best Companies to WorkFor, 2021
`
`Great Place to Work Ireland: Best Workplaces, 2021
`
`Great Place to Work Ireland: Best Workplaces for Women, 2021
`
`Fast Company: World Changing Ideas (Pandemic Response), 2021
`
`IDEA Pharma: Pharmaceutical Invention Index, 2021
`
`Science: Top Employer, 2020
`
`Fortune: Change the World, 2020
`
`Forbes: JUST Companies, 2020
`
`Dow JonesSustainability World Index, 2020
`
`Dow JonesSustainability North American Index, 2020
`
`Newsweek: America’s Most Responsible Companies, 2020
`
`Civic 50: Most Community-Minded Companies in the Nation, 2020 Great Places to Work: Best Workplacein Ireland, 2020
`
`Exhibit 2246
`
`Page 02 of 04
`
`2/4
`
`Exhibit 2246
`Page 02 of 04
`
`
`
`Led by science
`
`Weare the only biopharma companyfounded andled by physician-scientists since the
`beginning, more than three decades ago. From ourfirst days, science was and remains our
`central guiding principle. Our leadership includes multiple Nobel Laureates and five members
`of the National Academy of Sciences, and weare oneofthe first companies to form a Science
`and Technology Committee as an integral componentofits Board, a practice which has since
`becomeindustry standard.
`
`secrasneancrrasI
`
`>
`
`Featured perspectives
`
`The stories and opinions behind our work.
`
`meNemaseaef
`
`Sn oesaeTTTWATSS Homo0)a
`:
`Nee 3 ET lol)
`Soon MRee icse lar
`Eelerr
`eeeeda s leseL)
`
`SS EM le
`Senior Vice President, Corporate
`Communications and Citizenship
`
`A look back
`
`Science isn’t easy and new medicines aren't made over night. Decadesof investment and
`perseverance have broughtus to where wearetoday.
`
`Exhibit 2246
`
`Page 03 of 04
`
`3/4
`
`Exhibit 2246
`Page 03 of 04
`
`
`
`Contact us
`See our U.S. and Europeanlocations and contact information.
`
`A broad
`THD|
`collaborations
`
`Learn about our clinical-stage research
`partnerships and see how we're changing
`the landscape of medicine.
`
`oz:
`
`Industrial
`Operations and
`Product Supply
`
`Grounded in excellence and driven to
`continuously improve, our industry-
`leading l|OPS team is responsible for the
`production of our many medicines.
`
`eeicacauncomeanaus
`
`
`
`
`
`EXPLOREOPERATIONSOUR
`
`
`
`ae
`
`;
`
`5
`
`ie
`
`COVID-19PROGRAMANTIBODY
`
`Copyright © 2021 Regeneron Pharmaceuticals Inc.All rights reserved. All trademarks mentioned are the property oftheir respective owners.
`
`REGENERON termsotlse _SacialMediaTermsofTSS06):9NNO12117
`
`SCIENCE TO MEDICINE’
`Engagement
`CAREERS >
`y Ha] ffolieTHMelyPrivacyNotice
`
`1:11
`
`,
`
`
`
`Exhibit 2246
`
`Page 04 of 04
`
`Exhibit 2246
`Page 04 of 04
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
